Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects

Published:2005-08-01 Issue:21 Volume:11 Page:2779-2795
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Milella M.,Precupanu C.,Gregorj C.,Ricciardi M.,Petrucci M.,Kornblau S.,Tafuri A.,Andreeff M.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel molecular classification based on efferocytosis-related genes for predicting clinical outcome and treatment response in acute myeloid leukemia;Inflammation Research;2024-09-02

2. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial;Clinical Lymphoma Myeloma and Leukemia;2024-06

3. Design, synthesis and evaluation of novel thienopyridazine derivatives as Chk1/2 inhibitors;Bioorganic Chemistry;2022-04

4. Kinase Inhibitors and Interferons as Other Myeloid Differentiation Inducers in Leukemia Therapy;Acta Haematologica;2021-10-21

5. Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer;Expert Opinion on Investigational Drugs;2019-11-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP